ATE466569T1 - Nasale verabreichung von metoclopramid zur behandlung der gastroparese - Google Patents

Nasale verabreichung von metoclopramid zur behandlung der gastroparese

Info

Publication number
ATE466569T1
ATE466569T1 AT01922935T AT01922935T ATE466569T1 AT E466569 T1 ATE466569 T1 AT E466569T1 AT 01922935 T AT01922935 T AT 01922935T AT 01922935 T AT01922935 T AT 01922935T AT E466569 T1 ATE466569 T1 AT E466569T1
Authority
AT
Austria
Prior art keywords
gastroparesis
treatment
metoclopramide
nasal administration
nasal
Prior art date
Application number
AT01922935T
Other languages
English (en)
Inventor
Laura Lehman
David Tierney
Anastassios Retzios
Michael Petrone
David Young
Carol Trapnell
Ruth Oliver
Original Assignee
Evoke Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evoke Pharma Inc filed Critical Evoke Pharma Inc
Application granted granted Critical
Publication of ATE466569T1 publication Critical patent/ATE466569T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT01922935T 2000-03-30 2001-03-30 Nasale verabreichung von metoclopramid zur behandlung der gastroparese ATE466569T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19318100P 2000-03-30 2000-03-30
PCT/US2001/010356 WO2001074350A1 (en) 2000-03-30 2001-03-30 Nasal administration of agents for the treatment of gastroparesis

Publications (1)

Publication Number Publication Date
ATE466569T1 true ATE466569T1 (de) 2010-05-15

Family

ID=22712552

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01922935T ATE466569T1 (de) 2000-03-30 2001-03-30 Nasale verabreichung von metoclopramid zur behandlung der gastroparese

Country Status (12)

Country Link
US (2) US6770262B2 (de)
EP (1) EP1274414B1 (de)
KR (1) KR20030004361A (de)
AT (1) ATE466569T1 (de)
AU (1) AU2001249684A1 (de)
CA (1) CA2403994C (de)
CY (1) CY1111396T1 (de)
DE (1) DE60142037D1 (de)
DK (1) DK1274414T3 (de)
ES (1) ES2346290T3 (de)
PT (1) PT1274414E (de)
WO (1) WO2001074350A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040192781A1 (en) * 2003-03-31 2004-09-30 Haley Eugene T. Method of administration for metoclopramide and pharmaceutical formulation therefor
US20050137265A1 (en) * 2003-03-31 2005-06-23 Haley Eugene T. Rapidly dissolving metoclopramide solid oral dosage and method thereof
US6979562B2 (en) * 2003-11-18 2005-12-27 Ultra Biotech Limited Methods and compositions for treating gastroparesis
CA2550811C (en) * 2003-12-24 2012-05-01 Jane Hirsh Temperature-stable formulations, and methods of development thereof
MX2008004268A (es) * 2008-03-28 2009-09-28 Posi Visionary Solutions Llp Metoclopramida de liberacion prolongada de 24 horas.
MX2008004267A (es) * 2008-03-28 2009-09-28 Posi Visionary Solutions Llp Metoclopramida de liberacion prolongada de 12 horas.
US20130213393A1 (en) 2009-12-22 2013-08-22 Evoke Pharma, Inc. Nasal formulations of metoclopramide
PT2376075E (pt) 2008-12-22 2015-06-08 Evoke Pharma Inc Formulações nasais de metoclopramida
US10137113B2 (en) 2011-03-23 2018-11-27 Raqualia Pharma Inc. 5-HT4 receptor agonist as a prokinetic agent
PT2747561T (pt) * 2011-08-25 2018-09-28 Evoke Pharma Inc Tratamento de sintomas associados com a gastroparesia feminina
MX373078B (es) 2014-05-16 2020-07-03 Raqualia Pharma Inc Agonista del receptor 5-ht4 para gastroparesia.
CN104606136A (zh) * 2015-01-06 2015-05-13 中国人民解放军军事医学科学院毒物药物研究所 甲氧氯普胺鼻腔喷雾剂、其制备方法及用途
US11517545B2 (en) 2016-12-15 2022-12-06 Evoke Pharma, Inc. Treatment of moderate and severe gastroparesis
MX2020002682A (es) * 2017-09-11 2020-10-05 Evoke Pharma Inc Metodos de dosificacion intranasal de metoclopramida.
US11786512B2 (en) 2019-09-23 2023-10-17 Slayback Pharma Llc Stable pharmaceutical compositions of dihydroergotamine mesylate

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4624965A (en) 1984-11-15 1986-11-25 Nastech Pharmaceutical Co., Inc. Novel method of administering anti-nausea and anti-emetic pharmaceutical agents and novel dosage forms containing same
US5578628A (en) * 1985-06-25 1996-11-26 Glaxo Group Limited Medicaments for the treatment of nausea and vomiting
US4729997A (en) 1985-10-15 1988-03-08 Nastech Pharmaceutical Co., Inc. Novel method of administering meclizine type pharmaceutical agents and novel dosage forms containing same
FR2640139A1 (fr) 1988-12-14 1990-06-15 Delagrange Laboratoires Application de benzamides substitues comme gastromoteurs
CH681690A5 (en) 1990-09-28 1993-05-14 Kali Chemie Pharma Gmbh New metoclopramide salt compsns. with no additives
US5576317A (en) 1994-12-09 1996-11-19 Pfizer Inc. NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
US5760086A (en) 1996-03-14 1998-06-02 Ribogene, Inc. Nasal administration of agents for treatment of delayed onset emesis

Also Published As

Publication number Publication date
US20030059374A1 (en) 2003-03-27
DE60142037D1 (de) 2010-06-17
CA2403994A1 (en) 2001-10-11
US6770262B2 (en) 2004-08-03
EP1274414B1 (de) 2010-05-05
DK1274414T3 (da) 2010-08-30
CA2403994C (en) 2011-08-23
ES2346290T3 (es) 2010-10-14
CY1111396T1 (el) 2015-08-05
KR20030004361A (ko) 2003-01-14
WO2001074350A1 (en) 2001-10-11
EP1274414A1 (de) 2003-01-15
PT1274414E (pt) 2010-08-10
AU2001249684A1 (en) 2001-10-15
US20020065321A1 (en) 2002-05-30
EP1274414A4 (de) 2007-08-22

Similar Documents

Publication Publication Date Title
CY1111396T1 (el) Ρινικη χορηγηση μετοκλοπραμιδης για την αγωγη της γαστροπαρεσης
EA200300776A1 (ru) Производные фенэтаноламина для лечения респираторных заболеваний
AU5584901A (en) Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease
DK0927161T3 (da) Substitueret cyklisk amin-metalloproteaseinhibitorer
EE200100487A (et) Uudsed ühendid ja kompositsioonid proteaasiinhibiitoritena
NO20024005D0 (no) Pteridinforbindelser for behandling av psoriasis
DK1263729T3 (da) Cykliske azaforbindelser til anvendelse til behandling af serotoninrealterede sygdomme
DE60112766D1 (de) Verwendung von derivaten der valproinsäureamide und 2-valproinsäureamid zur behandlung und prävention von schmerzen und/oder kopfschmerzen
ATE389395T1 (de) Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson
SE0100569D0 (sv) New compounds
DK1458393T3 (da) Substituerede diketopiperaziner som oxytocinantagonister
DE60130661D1 (de) Verwendung der 13-cis retinsäure zur behandlung von emphysemen
ATE363474T1 (de) Benzimidazole zur behandlung sexueller fehlfunktionen
NO20025405D0 (no) Modulatorer for TNF-alfa-signalisering
ATE463242T1 (de) Behandlung von inkontinenz
EA200200948A1 (ru) Лечение псориаза
ATE489137T1 (de) Nasale verabreichung von substanzen zur behandlung der tardiven emesis
DE60015098D1 (de) 3-cyclopropylmethoxy-4-difluormethoxy-n-(3,5-dichlor-pyrid-4-yl)-benzamid zur behandlung von multipler sklerose
SE0004827D0 (sv) Therapeutic compounds
ATE308513T1 (de) Naphthamid-neurokinin antagonisten zur verwendung als medikamente
ATE536874T1 (de) Dreifache monoamin-wiederaufnahmehemmer zur behandlung von chronischen schmerzen
DE60330233D1 (de) Arsentherapie zur behandlung von autoimmunerkrankungen
ATE288254T1 (de) Methode zur behandlung von schlaganfall
DE50211752D1 (de) Wässrige lösungen von moxaverin zur behandlung der erektilen dysfunktion
DE60218726D1 (de) Verwendung von 4-oxo-butansäure derivaten zur behandlung der entzündung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1274414

Country of ref document: EP